FDA OKs Parkinson’s clinical trial to test NouvNeu001 cell therapy

The U.S. Food and Drug Administration (FDA) has given Iregene Therapeutics the green light to launch a clinical trial testing its cell therapy NouvNeu001, being developed for moderate to advanced Parkinson’s disease. According to the company, this marks a significant milestone, with NouvNeu001 becoming the world’s first…

FDA Clears NeuroOne Evo sEEG Device for Use Up to 30 Days

The U.S. Food and Drug Administration (FDA) has granted NeuroOne Medical Technologies clearance to market its Evo stereoelectroencephalography (sEEG) electrode technology for temporary use of less than 30 days. The device — previously cleared by the FDA for use of less than one day — is used to measure…